CELC:NSD-Celcuity Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 21.30

Change

0.00 (0.00)%

Market Cap

USD 0.33B

Volume

0.03M

Avg Analyst Target

USD 24.00 (+12.68%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

N/A

USD72.34B 115.77 63.37
IDXX IDEXX Laboratories, Inc

N/A

USD59.16B 89.27 65.72
DXCM DexCom, Inc

N/A

USD44.05B 87.51 108.08
EXAS Exact Sciences Corporation

N/A

USD20.23B N/A N/A
ICLR ICON Public Limited Company

N/A

USD17.35B 34.33 30.78
GH Guardant Health, Inc

N/A

USD12.06B N/A N/A
OZON Ozon Holdings PLC

N/A

USD11.24B N/A N/A
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
NTRA Natera, Inc

N/A

USD10.03B N/A N/A
SYNH Syneos Health, Inc

N/A

USD9.14B 47.18 22.93

ETFs Containing CELC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 131.27% 97% A+ 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 131.27% 97% A+ 96% A
Trailing 12 Months  
Capital Gain 281.04% 92% A- 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 281.04% 92% A- 96% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 14.03% 39% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.03% 39% F 58% F
Risk Return Profile  
Volatility (Standard Deviation) 94.05% 29% F 17% F
Risk Adjusted Return 14.91% 37% F 32% F
Market Capitalization 0.33B 39% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.13 26% F 16% F
Price / Cash Flow Ratio -45.56 93% A 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -38.03% 37% F 33% F
Return on Invested Capital -61.65% 29% F 13% F
Return on Assets -22.91% 29% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.24 63% D 39% F
Short Percent 8.13% 24% F 24% F
Beta 1.50 35% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector